New research from the CWMH.
It's World Menopause Day. October 18th was designated by the International Menopause Society (IMS) to raise awareness of the menopause and to support options to improve health and well-being for [...]
A recent review and meta-analysis found that upwards of 20% of women with no history of psychiatric illness experience their first bipolar-spectrum mood episode during the perinatal period.
A recent study shows the OCRDs, especially those that are more body-focused, have the potential to emerge or worsen during pregnancy and the postpartum, leading to high levels of comorbid depression and functional impairment.
Although a small sample, no major malformations were observed in a prospectively followed cohort of women with first trimester exposure to buspirone.
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
Second-generation antipsychotic medications associated with high metabolic risk (quetiapine, olanzapine, and clozapine) were associated with increased risk of gestational diabetes; other antipsychotics were not.
Prenatal exposure to antipsychotic medications was not associated with increased risk of neurodevelopmental disorders in offspring.
Further systematic research on outcomes after postpartum screening is needed to ensure that screening translates into improved clinical outcomes.
The most recent publication from the National Pregnancy Registry focuses on overall risk of malformations associated with the class of antipsychotic medications.
Despite the increasing use of the newer atypical or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including psychotic disorders, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little [...]
